REDWOOD CITY, CA--(Marketwire - April 14, 2008) - PDL BioPharma, Inc. (NASDAQ: PDLI) announced today two presentations of data at medical conferences related to the company’s development-stage antibody products in multiple sclerosis and oncology. Details regarding each of the presentations are summarized below. Copies of the poster and plenary presentations will be available on PDL BioPharma’s website at the time of publication.
